Research lines

• 1. Genomic profile of lymphoproliferative disorders

  Assessment of mutations and copy number alterations (exome and whole genome in some cases) of main lymphomas, including chronic lymphocytic leukemia (CLL), mantle-cell lymphomas (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and splenic marginal zone lymphomas (SMZL).

• 2. Cellular microenvironment in CLL and other lymphomas

  Microenvironment has demonstrated to be critical in the development of lymphomas, as well as the prognosis and the response to therapies, particularly to immunomodulators and small molecules with targeted action. In collaboration with other groups of IDIBAPS, we have a line of research to assess the microenvironment with pre-clinical and clinical models of response to specific treatments.

• 3. Prognostic models in lymphomas

  We have participated in several international initiatives to develop prognostic scores based in both clinical variables and biomarkers more related to the biology of the different lymphomas. In CLL and in FL papers on this field have been recently published.

• 4. Clinical trials in lymphoproliferative disorders, including advanced therapies

  Clinical research with new drugs from academic and pharma trials. Of note is the use of an academic CD-19 CAR- T cell developed in our institution, with clinical trials for acute lymphoblastic leukemia and CD19+ lymphoproliferative disorders.